查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1848861

临床试验影像市场按产品/服务、模式、治疗领域和最终用户划分 - 全球预测 2025-2032

Clinical Trial Imaging Market by Product & Service, Modality, Therapeutic area, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，临床试验影像市场将成长至 23.8 亿美元，复合年增长率为 6.92%。

关键市场统计数据
基准年 2024 13.9亿美元
预计年份：2025年 14.8亿美元
预测年份 2032 23.8亿美元
复合年增长率 (%) 6.92%

本文简要概述了临床试验影像技术如何发展成为一项综合性的策略能力，从而加速方案决策并增强监管机构的信心。

临床试验影像已发展成为现代药物研发的战略支柱，它整合了先进的成像技术、分析方法和操作流程，从而支持客观终点、安全性监测和患者分层。近年来，影像的应用已不再局限于辅助测量，而是成为方案设计、适应性试验策略和监管互动中的关键组成部分。这一转变反映了影像硬体技术的进步，以及能够协调不同中心和供应商提供的影像资料集的软体工具的同步发展。

因此，临床试验赞助者和研究者越来越重视研究计画早期阶段的影像策略。如今，跨职能团队与生物统计和临床营运部门协同工作，协调影像物流、供应商选择、品质保证和数据管治，以减少返工并加快结果解读。由此，一种分层式的影像方法——包括影像模式选择、集中式阅片流程和综合分析——已成为最佳实践，其核心在于可重复性和可解释性。

从各自独立的影像处理操作向一体化影像处理专案的转型需要有意识的变革管理、对供应商监管的投入以及互操作系统的采用。如果执行得当，这些投入将带来更可靠的终点指标、简化监管申报流程，并增强临床研究人员和相关人员（包括监管审查人员）的信心。本执行摘要探讨了影响市场格局的因素、收费标准的影响、市场细分洞察、区域发展、竞争动态、可操作的建议、调查方法的严谨性，以及如何取得完整报告以获取更深入的说明。

融合技术、监管核准和不断演变的营运模式如何再形成临床试验影像生态系统和决策路径

临床试验影像领域正经历一场变革性的转变，其驱动力包括技术融合、监管机构对客观终点的重视以及不断演进的运作模式。人工智慧和进阶分析技术如今已能有效补充传统的放射学评估，提供自动分割、定量生物标记提取和异常检测等功能，从而降低变异性并提高对治疗效果的敏感性。随着这些功能的普及，申办者和影像服务供应商正在采用混合工作流程，将自动化预处理与盲法专家审查相结合，以确保临床有效性。

同时，监管机构对基于影像学终点指标的认可度日益提高，这些指标需采用标准化的采集和检验的分析流程，从而鼓励申办方在试验方案生命週期的早期阶段就纳入影像学策略。监管机构的这种认可正在推动对影像核心实验室、集中式阅片模式和严格的品质保证框架的投资。在营运层面，供应商整合和平台统一化正在显着降低多中心、全球性试验的复杂性并提高资料可追溯性。

最后，支付方和卫生经济相关人员越来越重视影像生物标记的实际应用价值，这影响终点选择和长期证据规划。这种转变迫使医疗机构重新评估自身能力，优先考虑可互操作系统，并建立伙伴关係，以加速部署符合临床和商业性目标的强大影像专案。

针对近期关税调整对诊断影像专案设备流通、供应商选择和供应链弹性造成影响的实际考量和营运调整

近期一些地区对医疗设备、零件及相关服务征收的关税，为临床试验影像处理流程带来了新的考量，尤其对于依赖跨境运输扫描仪、配件及专用硬体的国际研究而言更是如此。关税带来的成本压力可能会影响设备采购时机、维护计画以及现场服务与集中服务等决策。事实上，临床试验赞助者和影像诊断服务机构正在权衡各种利弊，例如本地采购设备、将影像判读外包给区域核心实验室，或利用云端託管来最大限度地减少人员流动。

为此，许多相关人员探索了在地采购策略，并协商签署了长期服务协议，以在保证资料品质和合规性的同时，稳定整体拥有成本。这些策略强调与区域供应商建立合作关係，以减少资本设备跨境运输的频率，并提供及时的技术支援和遵守标准化的采购通讯协定。此外，供应链路线的调整也促使采购、临床营运和供应商伙伴关係团队之间进行更紧密的合作，以确保正在进行的临床试验影像能力的持续性。

重要的是，各公司也在审查合约条款，包括关税紧急条款和灵活的服务等级协议，以应对潜在的贸易中断。关税虽然增加了复杂性，但也促使企业制定更灵活的营运计画、建构多元化的供应商网络，并更注重区域内的能力建设，从而保障临床实验的进度和数据的完整性。

透过深度细分洞察，使产品和服务、成像方式、治疗重点和最终用户期望与业务和临床需求保持一致。

以细分市场为重点的分析揭示了产品/服务连续体、成像方式、治疗领域和最终用户类别中清晰的优先事项和营运需求。依产品/服务划分，市场研究分为服务及软体两类，其中服务又细分为影像操作服务、先导化合物分析服务、系统及技术支援服务及试验设计及咨询服务。以影像方式划分，包括电脑断层扫描（CT）、超音波心动图、磁振造影）、正子断层扫描（PET）、超音波和X射线，每种影像方式都有其独特的成像通讯协定、品管和分析需求，这些都会影响供应商的选择和训练要求。

按治疗领域划分，此生态系涵盖内分泌学、免疫学、感染疾病、神经病学和肿瘤学。肿瘤学试验通常需要多参数成像和长期随访，而神经病学试验则侧重于标准化的认知和结构成像终点。按最终用户划分，该生态系统包括学术和政府研究机构、生物技术公司、委外研发机构和製药公司，每个机构都有各自的采购时间表、监管要求和创新动力。例如，学术中心通常优先考虑调查方法的严谨性和新型生物标誌物，而商业赞助商则通常优先考虑可扩展性、成本可预测性和结果读取时间。

综上所述，这些细分维度凸显了灵活的服务架构、特定模式的标准操作规程以及客户参与模式的重要性，这些模式能够使技术能力与治疗目标和最终用户需求保持一致。策略供应商和申办者若能依照这些维度调整其服务，将实现更高的营运效率，并更好地与临床试验目标相契合。

关键全球区域的基础设施、监管差异和营运能力如何影响临床试验影像策略和执行

区域动态对影像操作、供应商生态系统以及与监管机构的互动有显着影响，不同区域的能力、基础设施和协作网路模式各不相同。在美洲，先进的影像基础设施、庞大的影像核心实验室以及高度普及的数位化工作流程为复杂的多中心临床试验提供了支援。然而，营运挑战包括地理距离、各中心能力差异以及在异质性临床环境中实现高度标准化的必要性。因此，申办方通常倾向于采用集中阅片与区域技术支援相结合的方式，以平衡品质和物流。

在欧洲、中东和非洲，监管环境的多样性和影像基础设施的差异，使得通讯协定的严格协调、标准操作规程的跨语言翻译以及严谨的设施认证流程成为必要。该地区拥有强大的学术中心和成熟的合作网络，如果申办方投资于前期培训和平台互通性，则有利于进行跨国研究。此外，区域供应商通常能够提供宝贵的本地技术支持，并加快设备部署速度。

对影像硬体的快速投资、临床研究能力的拓展以及本地CRO能力的提升，使得亚太地区进行大规模临床试验的吸引力日益增强。然而，临床实践模式、资料保护框架以及影像技术应用率的差异，要求制定独特的影像策略，重点关注早期中心评估和扩充性的云端基础解决方案。任何地区的成功都取决于积极的区域参与、标准化的资料收集通讯协定以及健全的品质保证体系，这些体系能够弥合区域差异，并确保汇总分析的资料完整性。

竞争格局洞察：专业供应商、软体创新者、核心实验室和CRO联盟如何为临床试验建立差异化的端到端影像解决方案

临床试验影像领域的竞争格局反映了专业服务供应商、软体创新者、影像核心实验室和整合供应商联盟的整合，共同建构了服务交付模式。领先的影像公司透过提供检验的阅片平台、特定模态的专业知识和咨询式研究设计服务来脱颖而出，帮助申办方将临床假设转化为可靠的影像终点。同时，提供可扩展分析、安全云端储存和符合监管标准的审核追踪的软体公司，正成为多供应商编配和资料管治的核心参与者。

影像服务公司与科技公司之间的伙伴关係十分普遍，从而能够提供端到端的提案，包括现场培训、集中阅片和高级后处理。合约研究组织正透过组织或策略联盟整合影像能力，拓展其服务范围，为申办方提供简化供应商管理的单一供应商解决方案。学术中心和专业研究机构持续贡献方法创新和检验研究，为最佳实践和监管对话提供资讯。

买方在进行竞争性评估时，应优先考虑检测模式的过往记录、检验的分析流程、监管合规历史以及支援全球临床临床实验的营运能力。能够证明跨模式互通性、透明的品质指标和可自订服务等级的供应商通常具有竞争优势。最终，市场更青睐那些能够降低复杂性、提供可追溯的审核追踪并将技术交付与临床目标相结合的合作伙伴。

诊断影像专案领导者可以采取哪些策略措施来互通性、检验的分析和早期方案调整，以降低临床试验风险并提高数据效用？

产业领导者应采取策略性策略，整合技术投资、严格的营运规范和伙伴关係关係，以提升临床试验影像计画的有效性。首先，检验互通性，选择支援标准化采集通讯协定和安全性、审核资料传输的平台和供应商。其次，应采用自动化分析作为专家审核的补充，利用经过验证的演算法加快预处理速度并标记品质问题，同时保持最终终点决策的盲法裁决。

其次，应投资于早期影像策略的製定，将影像专家纳入方案设计，并将影像方式的选择、扫描时机和解读范式与临床终点和监管要求相匹配。这种方法可以最大限度地减少返工，并降低影像资料无法读取或使用的风险。此外，应透过建立区域供应商网路和灵活的合约条款（包括应对关税相关突发情况和区域设备支援），确保不同地区影像处理能力的连续性。最后，应建立管治机制，强制执行透明的品质指标、定期的实验室间校准以及明确的影像处理交付课责。透过实施这些措施，申办者和服务供应商可以减少营运摩擦，提高资料完整性，并加速影像在临床专案中的转换应用。

采用严格的混合方法，结合相关人员访谈、二手证据综合和资料三角验证，确保获得可靠且可操作的影像学发现。

本研究采用混合方法，以确保研究的严谨性、可重复性和对决策者的相关性。调查方法结合了对行业相关人员（包括影像科主任、临床运营主任和科学顾问）的定性访谈，以及对公开的监管指南、临床试验註册资讯、技术白皮书和同行评审文献的全面二次分析。主要访谈着重于营运挑战、供应商选择标准、特定成像方式的考量因素以及区域实施瓶颈，从而为二次分析结果提供了循证观点。

为验证主题的有效性并协调不同观点，调查团队采用了资料三角验证法。他们综合了程序标准、技术规格以及实际实施中所学到的经验教训，并制定了切实可行的建议。品质保证程序包括对访谈记录进行交叉检验、检查不同资料来源的一致性以及专家同行评审，以确保分析结论的可靠性。在适用的情况下，研究记录了调查方法的注意事项和假设，以帮助读者根据研究范围以及不断变化的监管和技术环境来解读研究结果。

最后，这种方法强调了资料来源和解释步骤的透明度，使读者能够追溯结论的来源输入，并了解营运现实和技术创新如何影响分析框架。

对整合影像策略、检验分析和操作稳健性如何决定临床试验的成功和证据可靠性进行总结性审查。

临床试验影像在证据生成过程中扮演核心角色，它提供客观、可重复的指标，为临床决策和监管互动提供支持。先进成像技术、自动化分析和整合服务模式的相互作用，为提高终点敏感度、降低变异性以及加快获得有效结果创造了机会。同时，成像技术异质性、区域差异以及不断变化的交易考量所带来的操作复杂性，需要周密的规划、供应商管治以及对互操作系统的投资。

展望未来，那些优先将影像策略早期整合到通讯协定设计中、负责任地运用检验的分析方法并建立稳健的供应商网路的机构，将能够更好地利用影像技术作为策略差异化优势。同时，严格的品质保证、透明的绩效指标以及与监管机构和科学界相关人员的密切合作，对于将影像数据转化为可靠的临床证据仍然至关重要。这些措施将共同强化影像技术在各个治疗领域和终端使用者中的作用，从而为临床计画和更广泛的医疗保健系统相关人员带来更清晰、更可靠的结果。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将人工智慧演算法整合到肿瘤影像研究中，以实现病灶的自动定量分析
  • 实施云端基础的影像资料平台，以支援全球各地临床试验中心的分散式工作流程。
  • 开发用于临床试验中早期检测心血管治疗效果的定量影像生物标记
  • 新兴的PET/MRI混合通讯协定可用于增强神经退化性疾病研究中的多参数评估
  • 在分散式临床试验中实施用于远端患者监护的即时行动成像设备
  • 跨国药物研发研究中标准化影像终点检验的法规结构正在不断发展

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：临床试验影像市场（依产品及服务划分）

  • 服务
    • 营运影像服务
    • 分析服务
    • 系统和技术支援服务
    • 测试设计和咨询服务
  • 软体

9. 临床试验影像市场依影像方式划分

  • 电脑断层扫描
  • 心臟超音波图
  • 磁振造影
  • 正子断层扫描
  • 超音波
  • X射线

第十章：依治疗领域分類的临床试验影像市场

  • 内分泌学
  • 免疫疾病
  • 感染疾病
  • 神经病学
  • 肿瘤学

第十一章 临床试验影像市场（依最终使用者划分）

  • 学术和政府研究机构
  • 生技公司
  • 合约研究组织
  • 製药公司

第十二章：按地区分類的临床试验影像市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：按组别分類的临床试验影像市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：各国临床试验影像市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Alimentiv Inc.
    • Anagram 4 Clinical Trials
    • Biospective Inc.
    • Boston Imaging Core Lab LLC
    • Cardiovascular Imaging Technologies LLC
    • Clario
    • GE HealthCare Technologies Inc.
    • Icon PLC
    • Image Core Lab Private Limited
    • Imaging Endpoints II LLC
    • Ixico PLC
    • Median Technologies
    • Medical Metrics Inc. by Catalent, Inc.
    • Medidata by Dassault Systemes
    • Medpace, Inc.
    • Micron Inc.
    • Perceptive Informatics LLC
    • ProScan Imaging LLC
    • Resonance Health Ltd.
    • Voiant Clinical
    • WCG Clinical, Inc.
Product Code: MRR-501246435DF5

The Clinical Trial Imaging Market is projected to grow by USD 2.38 billion at a CAGR of 6.92% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.39 billion
Estimated Year [2025] USD 1.48 billion
Forecast Year [2032] USD 2.38 billion
CAGR (%) 6.92%

A concise orientation to how clinical trial imaging has evolved into an integrated, strategic capability that accelerates protocol decisions and regulatory confidence

Clinical trial imaging has matured into a strategic pillar of contemporary drug development, integrating advanced modalities, analytics, and operational workflows to support objective endpoints, safety monitoring, and patient stratification. Over recent years, imaging has expanded beyond a supporting measurement to become a decisive element in protocol design, adaptive trial strategies, and regulatory interactions. This shift reflects both technological advancements in acquisition hardware and the parallel evolution of software tools capable of harmonizing heterogeneous imaging datasets across sites and vendors.

As a result, sponsors and trial operators increasingly prioritize imaging strategy at earlier stages of study planning. Cross-functional teams now coordinate imaging logistics, vendor selection, quality assurance, and data governance in tandem with biostatistics and clinical operations, thereby reducing rework and accelerating readouts. Consequently, a layered approach to imaging-encompassing modality selection, centralized reading paradigms, and integrated analytics-has emerged as best practice where reproducibility and interpretability are critical.

Transitioning from isolated imaging tasks to a unified imaging program requires deliberate change management, investment in vendor oversight, and the adoption of interoperable systems. When executed well, these investments yield more defensible endpoints, streamlined regulatory submissions, and enhanced confidence across stakeholder groups, including clinical investigators and regulatory reviewers. The remainder of this executive summary explores the forces reshaping the landscape, tariff implications, segmentation-driven insights, regional dynamics, competitive activity, actionable recommendations, methodological rigor, and an invitation to procure the full report for deeper guidance.

How converging technologies, regulatory acceptance, and evolving operational models are reshaping the clinical trial imaging ecosystem and decision pathways

The clinical trial imaging landscape is experiencing transformative shifts driven by technology convergence, regulatory emphasis on objective endpoints, and evolving operational models. Artificial intelligence and advanced analytics now complement traditional radiologic assessment by offering automated segmentation, quantitative biomarker extraction, and anomaly detection that decrease variability and enhance sensitivity to treatment effects. As these capabilities become more accessible, sponsors and imaging service providers are adopting hybrid workflows that blend automated pre-processing with blinded expert reads to maintain clinical validity.

Concurrently, regulatory authorities have signaled greater receptivity to imaging-derived endpoints when supported by standardized acquisition and validated analytic pipelines, prompting sponsors to embed imaging strategy earlier in the protocol lifecycle. This regulatory receptivity encourages investments in imaging core labs, centralized reading models, and rigorous quality assurance frameworks. Operationally, there is a pronounced movement toward vendor consolidation and platform unification to reduce complexity and improve data traceability across multi-center, global trials.

Finally, payer and health economics stakeholders increasingly evaluate the real-world applicability of imaging biomarkers, which is influencing endpoint selection and long-term evidence plans. Together, these shifts compel organizations to reassess capabilities, prioritize interoperable systems, and cultivate partnerships that accelerate deployment of robust imaging programs aligned to clinical and commercial objectives.

Practical considerations and operational adaptations driven by recent tariff adjustments that affect equipment flows, vendor selection, and supply chain resilience for imaging programs

The recent imposition of tariffs affecting medical equipment, components, and associated services in some jurisdictions has introduced new considerations for clinical trial imaging operations, particularly in global studies that rely on cross-border shipment of scanners, accessories, and specialized hardware. Tariff-related cost pressures can influence timing for equipment procurement, maintenance scheduling, and decisions around on-site versus centralized services. In practice, sponsors and imaging service organizations evaluate the trade-offs between procuring equipment locally, outsourcing imaging reads to regional core labs, or leveraging cloud-hosted analytics to minimize physical transfers.

In response, many stakeholders have explored localized sourcing strategies and negotiated longer-term service agreements to stabilize total cost of ownership while preserving data quality and regulatory compliance. This strategy reduces the frequency of cross-border movements of capital equipment and emphasizes partnerships with regional vendors that can provide timely technical support and adherence to standardized acquisition protocols. Moreover, shifts in supply chain routing have encouraged closer collaboration between procurement, clinical operations, and vendor management teams to ensure continuity of imaging capacity for ongoing trials.

Importantly, organizations are also reviewing contracting terms to include tariff contingency clauses and flexible service-level agreements that account for potential trade disruptions. While tariff measures introduce complexity, they also motivate more resilient operational planning, diversified supplier networks, and greater emphasis on in-region capabilities that can safeguard trial timelines and data integrity.

Detailed segmentation-driven insights that align product/service offerings, imaging modalities, therapeutic priorities, and end-user expectations to operational and clinical requirements

Segment-focused analysis reveals distinct priorities and operational requirements across the product and service continuum, modalities, therapeutic areas, and end-user categories. Based on Product & Service, market study groups Services and Software, where Services is further clarified into Operational Imaging Services, Read Analysis Services, System & Technical Support Services, and Trial Design & Consulting Services; this segmentation highlights that clients often purchase bundled service models that combine hands-on site support with centralized analytics to maintain consistency across global sites. Based on Modality, the landscape encompasses Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Ultrasound, and X-Ray, each modality presenting unique acquisition protocols, quality controls, and analytic needs that affect vendor selection and training requirements.

Therapeutic nuance matters as well; based on Therapeutic area, studies span Endocrinology, Immunological Disorder, Infectious Diseases, Neurology, and Oncology, with oncology trials frequently demanding multi-parametric imaging and longer follow-up while neurology trials emphasize standardized cognitive and structural imaging endpoints. Based on End-User, the ecosystem includes Academic & Government Research Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, where each end-user brings its own procurement cadence, regulatory expectations, and appetite for innovation. For instance, academic centers may prioritize methodological rigor and novel biomarkers, whereas commercial sponsors often emphasize scalability, cost predictability, and time to readout.

Taken together, these segmentation vectors underscore the importance of flexible service architectures, modality-specific standard operating procedures, and targeted client engagement models that align technical capabilities with therapeutic intent and end-user requirements. Strategic vendors and sponsors that tailor their offerings across these dimensions achieve higher operational efficiency and better alignment with trial goals.

How regional infrastructure, regulatory diversity, and operational capacity across major global regions influence clinical trial imaging strategy and execution

Regional dynamics exert a material influence on imaging operations, vendor ecosystems, and regulatory interactions, with distinct regional patterns in capacity, infrastructure, and collaborative networks. In the Americas, advanced imaging infrastructure, a large base of imaging core laboratories, and high adoption of digital workflows support complex, multi-center trials; however, operational challenges include geographic distances, variable site capabilities, and the need for robust standardization across heterogeneous clinical settings. Consequently, sponsors often favor centralized reading combined with regional technical support to balance quality and logistics.

In Europe, Middle East & Africa, regulatory diversity and variable imaging infrastructure necessitate meticulous harmonization of protocols, translation of standard operating procedures across languages, and careful site qualification processes. The region benefits from strong academic centers and established collaborative research networks, which facilitate multi-country studies if sponsors invest in upfront training and platform interoperability. In addition, regional vendors often provide valuable localized technical support and faster equipment deployment timelines.

In Asia-Pacific, rapid investments in imaging hardware, expanding clinical research capacity, and growing local CRO capabilities have increased the region's appeal for large-scale trials. Nevertheless, differences in clinical practice patterns, data protection frameworks, and modality penetration require tailored imaging strategies that emphasize early site assessment and scalable cloud-based solutions. Across all regions, success depends on proactive local engagement, standardized acquisition protocols, and robust QA programs that bridge regional variability and preserve data integrity for pooled analyses.

Competitive landscape insights showing how specialized providers, software innovators, core labs, and CRO alliances create differentiated end-to-end imaging solutions for trials

Competitive dynamics in clinical trial imaging reflect a blend of specialized service providers, software innovators, imaging core labs, and integrated vendor alliances that together shape service delivery models. Leading imaging organizations differentiate by offering validated reading platforms, modality-specific expertise, and consultative trial design services that help sponsors translate clinical hypotheses into robust imaging endpoints. At the same time, software companies that deliver scalable analytics, secure cloud storage, and regulatory-grade audit trails are increasingly central to multi-vendor orchestration and data governance.

Partnerships between imaging services and technology firms are common, enabling an end-to-end proposition that combines site training, centralized reads, and advanced post-processing. Contract Research Organizations expand their portfolios by incorporating imaging capabilities either organically or through strategic alliances, thereby offering sponsors single-vendor solutions that streamline vendor management. Academic centers and specialty research institutes continue to contribute methodological innovation and validation studies that inform best practices and regulatory dialogue.

For purchasers, competitive evaluation should prioritize demonstrated modality experience, validated analytic pipelines, regulatory compliance history, and the operational capacity to support global trials. Vendors that can demonstrate cross-modal interoperability, transparent quality metrics, and customizable service tiers generally hold a competitive edge. Ultimately, the market favors collaborators who can reduce complexity, provide traceable audit trails, and align technical delivery with clinical objectives.

Actionable strategic moves for imaging program leaders to integrate interoperability, validated analytics, and early protocol alignment to de-risk trials and enhance data utility

Industry leaders should adopt a strategic posture that integrates technological investment, operational rigor, and collaborative partnerships to elevate the effectiveness of clinical trial imaging programs. First, prioritize interoperability by selecting platforms and vendors that support standardized acquisition protocols and secure, auditable data transfer; such choices reduce downstream variability and facilitate pooled analyses. Second, incorporate automated analytics as a complement to expert reads, using validated algorithms to accelerate pre-processing and flag quality issues while preserving blinded adjudication for final endpoint determination.

Next, invest in early-stage imaging strategy development by embedding imaging experts in protocol design to align modality selection, timing of scans, and read paradigms with clinical endpoints and regulatory expectations. This approach minimizes rework and mitigates the risk of unreadable or unusable imaging data. Additionally, cultivate regional supplier networks and flexible contracting terms that account for tariff-related contingencies and localized equipment support, ensuring continuity of imaging capacity across diverse geographies. Finally, establish transparent quality metrics, regular cross-site calibration exercises, and governance mechanisms that assign clear accountability for imaging deliverables. By implementing these measures, sponsors and service providers can reduce operational friction, enhance data integrity, and accelerate the translational value of imaging within clinical programs.

A rigorous mixed-methods approach combining stakeholder interviews, secondary evidence synthesis, and data triangulation to ensure reliable and actionable imaging insights

This research employed a mixed-methods approach to ensure rigor, reproducibility, and relevance for decision-makers. The methodology combined primary qualitative engagement with industry stakeholders, including imaging directors, clinical operations leads, and scientific advisors, with comprehensive secondary analysis of publicly available regulatory guidance, clinical trial registries, technical white papers, and peer-reviewed literature. Primary interviews focused on operational challenges, vendor selection criteria, modality-specific considerations, and regional execution bottlenecks, providing grounded perspectives that contextualize secondary findings.

Data triangulation was applied throughout to validate themes and reconcile divergent viewpoints. The research team synthesized procedural standards, technical specifications, and real-world implementation lessons to produce actionable recommendations. Quality assurance procedures included cross-validation of interview transcripts, consistency checks across data sources, and peer review by domain experts to ensure the reliability of analytical conclusions. Where applicable, methodological caveats and assumptions were documented to help readers interpret findings in light of study scope and the evolving regulatory and technological environment.

Finally, the approach emphasized transparency in data provenance and interpretive steps, enabling readers to trace conclusions back to source inputs and understand how operational realities and technological innovations informed the analytic framework.

Concluding synthesis of how integrated imaging strategy, validated analytics, and operational resilience together determine trial success and evidence credibility

Clinical trial imaging now occupies a central role in the evidence generation pathway, offering objective, reproducible measures that support clinical decision-making and regulatory dialogue. The interplay of advanced modalities, automated analytics, and integrated service models creates opportunities to enhance endpoint sensitivity, reduce variability, and accelerate time to meaningful readouts. At the same time, operational complexity-driven by modality heterogeneity, regional differences, and evolving trade considerations-demands deliberate planning, vendor governance, and investment in interoperable systems.

Looking ahead, organizations that prioritize early integration of imaging strategy into protocol design, adopt validated analytics responsibly, and cultivate resilient supplier networks will be better positioned to harness imaging as a strategic differentiator. In parallel, rigorous quality assurance, transparent performance metrics, and close collaboration with regulatory and scientific stakeholders will remain essential to translating imaging data into credible clinical evidence. Collectively, these actions will strengthen the role of imaging across therapeutic areas and end-users, delivering clearer, more reliable outcomes for both clinical programs and broader health system stakeholders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence algorithms for automated lesion quantification in oncological imaging trials
  • 5.2. Adoption of cloud-based imaging data platforms to enable decentralized clinical trial workflows across global sites
  • 5.3. Development of quantitative imaging biomarkers for early detection of cardiovascular treatment efficacy in trials
  • 5.4. Emergence of hybrid PET/MRI protocols for enhanced multiparametric assessment in neurodegenerative disorder studies
  • 5.5. Implementation of real-time mobile imaging devices for remote patient monitoring in decentralized clinical trials
  • 5.6. Evolution of regulatory frameworks for standardized imaging endpoint validation in multinational drug development studies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Clinical Trial Imaging Market, by Product & Service

  • 8.1. Services
    • 8.1.1. Operational Imaging Services
    • 8.1.2. Read Analysis Services
    • 8.1.3. System & Technical Support Services
    • 8.1.4. Trial Design & Consulting Services
  • 8.2. Software

9. Clinical Trial Imaging Market, by Modality

  • 9.1. Computed Tomography
  • 9.2. Echocardiography
  • 9.3. Magnetic Resonance Imaging
  • 9.4. Positron Emission Tomography
  • 9.5. Ultrasound
  • 9.6. X-Ray

10. Clinical Trial Imaging Market, by Therapeutic area

  • 10.1. Endocrinology
  • 10.2. Immunological Disorder
  • 10.3. Infectious Diseases
  • 10.4. Neurology
  • 10.5. Oncology

11. Clinical Trial Imaging Market, by End-User

  • 11.1. Academic & Government Research Institutes
  • 11.2. Biotechnology Companies
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical Companies

12. Clinical Trial Imaging Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Clinical Trial Imaging Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Clinical Trial Imaging Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Alimentiv Inc.
    • 15.3.2. Anagram 4 Clinical Trials
    • 15.3.3. Biospective Inc.
    • 15.3.4. Boston Imaging Core Lab LLC
    • 15.3.5. Cardiovascular Imaging Technologies LLC
    • 15.3.6. Clario
    • 15.3.7. GE HealthCare Technologies Inc.
    • 15.3.8. Icon PLC
    • 15.3.9. Image Core Lab Private Limited
    • 15.3.10. Imaging Endpoints II LLC
    • 15.3.11. Ixico PLC
    • 15.3.12. Median Technologies
    • 15.3.13. Medical Metrics Inc. by Catalent, Inc.
    • 15.3.14. Medidata by Dassault Systemes
    • 15.3.15. Medpace, Inc.
    • 15.3.16. Micron Inc.
    • 15.3.17. Perceptive Informatics LLC
    • 15.3.18. ProScan Imaging LLC
    • 15.3.19. Resonance Health Ltd.
    • 15.3.20. Voiant Clinical
    • 15.3.21. WCG Clinical, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CLINICAL TRIAL IMAGING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CLINICAL TRIAL IMAGING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CLINICAL TRIAL IMAGING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 253. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 256. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 257. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 258. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 259. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 260. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 261. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 262. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 263. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 264. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 280. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 281. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 282. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 289. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 292. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 293. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 294. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 295. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 296. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 297. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 298. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 299. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 300. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 301. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 304. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 305. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 306. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 307. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 308. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 309. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 310. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 311. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 312. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 316. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 317. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 318. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MI